Sign in
4

Changes in Ownership

Serina Therapeutics, Inc. Filed Acc 0001301120-26-000004

Chief Scientific Officer sold 6,500 shares at an average $2.50 ($16,253)

  • Chief Scientific Officer acquired 6,500 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Moreadith Randall · Chief Scientific Officer

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2026-01-13 Exercise or conversion : show line 1 in the form 10b5-1 +5,416 $0.06 $325 5,416 D
2026-01-13 Sale : show line 2 in the form 10b5-1 −5,416 $2.50 $13,540 0 D
2026-01-14 Exercise or conversion : show line 3 in the form 10b5-1 +1,084 $0.06 $65 1,084 D
2026-01-14 Sale : show line 4 in the form 10b5-1 −1,084 $2.50 $2,713 0 D
Open-market sales · 6,500 sh · avg $2.50 · $16,253

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2026-01-13 Exercise or conversion : show line 5 in the form 10b5-1 Stock Option (right to buy) −5,416 333,770 D
2026-01-14 Exercise or conversion : show line 6 in the form 10b5-1 Stock Option (right to buy) −1,084 332,686 D
Loading xslF345X05/wk-form4_1768413405.xml…